摘要 |
The present disclosure provides PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, comprising an extracellular domain of PDGFRbeta, or a biologically active fragment thereof, a linker and a Fc domain, wherein said fusion protein binds one or more of platelet-derived growth factor ligands with high affinity. The PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, accordingly, can be used to treat pathological neovascularization and fibrosis, e.g. cancer, ocular neovascular disorders or nephropathies. The disclosure also provides methods for treating ocular neovascular disorders with these fusion proteins without increasing vascular leakage. Such PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, exhibit increased terminal half time in the eye. Also provided are nucleic acid sequences encoding the foregoing PDGFRbeta-Fc fusion proteins, or biologically active fragments thereof, vectors containing the same, pharmaceutical compositions and kits with instructions for use. |
申请人 |
BAYER PHARMA AKTIENGESELLSCHAFT |
发明人 |
LINDEN, LARS;SCHLANGE, THOMAS;WILMEN, ANDREAS;TRAUTWEIN, MARK;SCHOMBER, TIBOR;BÖTTGER, MICHAEL;KLAR, JÜRGEN;GREVEN, SIMONE |